Basit öğe kaydını göster

dc.contributor.authorDe Porre, Peter
dc.contributor.authorLi, Susan
dc.contributor.authorMundle, Suneel
dc.contributor.authorTran, Namphuong
dc.contributor.authorFizazi, Karim
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorChi, Kim N.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorRodriguez-Antolin, Alfredo
dc.contributor.authorFeyerabend, Susan
dc.contributor.authorFein, Luis
dc.contributor.authorAlekseev, Boris Y.
dc.contributor.authorSulur, Giri
dc.contributor.authorProtheroe, Andrew
dc.date.accessioned2021-03-02T19:17:34Z
dc.date.available2021-03-02T19:17:34Z
dc.date.issued2020
dc.identifier.citationMatsubara N., Chi K. N. , ÖZGÜROĞLU M., Rodriguez-Antolin A., Feyerabend S., Fein L., Alekseev B. Y. , Sulur G., Protheroe A., Li S., et al., "Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study", EUROPEAN UROLOGY, cilt.77, ss.494-500, 2020
dc.identifier.issn0302-2838
dc.identifier.othervv_1032021
dc.identifier.otherav_e1e0cd75-bfcd-4b8b-bb07-87497c14788e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/5576
dc.identifier.urihttps://doi.org/10.1016/j.eururo.2019.11.021
dc.description.abstractBackground: LATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC).
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.titleCorrelation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study
dc.typeMakale
dc.relation.journalEUROPEAN UROLOGY
dc.contributor.departmentNational Cancer Center - Japan , ,
dc.identifier.volume77
dc.identifier.issue4
dc.identifier.startpage494
dc.identifier.endpage500
dc.contributor.firstauthorID2280337


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster